Accession

P24593

GeneID

3488

Source

E.coli-derived HumanIGF-BP5 protein,Leu21-Glu272.

Molecular Weight

Approximately 28.6 kDa.

AA Sequence

LGSFVHCEPC DEKALSMCPP SPLGCELVKE PGCGCCMTCA LAEGQSCGVY TERCAQGLRC LPRQDEEKPL HALLHGRGVC LNEKSYREQV KIERDSREHE EPTTSEMAEE TYSPKIFRPK HTRISELKAE AVKKDRRKKL TQSKFVGGAE NTAHPRIISA PEMRQESEQG PCRRHMEASL QELKASPRMV PRAVYLPNCD RKGFYKRKQC KPSRGRKRGI CWCVDKYGMK LPGMEYVDGD FQCHTFDSSN VE

Tag

None

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Purity

> 96% by SDS-PAGE and HPLC analyses.

Biological Activity

Fully biologically active when compared to standard. The ED₅₀ as determined by its ability to inhibit IGF-II induced proliferation of MCF-7 cells is less than 0.4 μg/mL, corresponding to a specific activity of > 2500 IU/mg in the presence of 15 ng/mL of rHuIGF-II.

Endotoxin

< 0.1 EU per 1μg of the protein by the LAL method.

Formulation

Lyophilized from a 0.2 μm filtered concentrated solution in 10 mM Sodium Citrate, pH 3.0.

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.